Literature DB >> 9101432

Structural determinants for the interaction of lipopolysaccharide binding protein with purified high density lipoproteins: role of apolipoprotein A-I.

T Massamiri1, P S Tobias, L K Curtiss.   

Abstract

The interaction of lipopolysaccharide binding protein (LBP) with apolipoprotein (apo)A-I on high density lipoproteins (HDL) was studied in solid phase ligand binding assays with a biotinylated LBP-specific antibody. The association was dependent on LBP concentration and enhanced in the presence of lipopolysaccharide (LPS). Maximal enhancement was measured at an LPS/LBP molar ratio of 6. To identify regions on apoA-I that participate directly or indirectly in the interaction between LBP and HDL, we attempted to inhibit LBP association with a panel of mapped apoA-I-specific monoclonal antibodies. Whereas some antibodies were effective inhibitors, others were not, even though they bound apoA-I. Furthermore, selected apoA-I synthetic peptides inhibited the antibody-mediated interference of the HDL/LBP interaction. Although no specific mechanism can be defined for the basis of the inhibitory effects of the antibodies on the association of LBP with HDL, we identified a role for three unique regions on apoA-I between residues 1-31, 95-164, and 178-200. These results suggested that apoA-I is a key component in the association of LBP with HDL and may play an important role in the biologic activity of LPS/LBP complexes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9101432

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  13 in total

1.  Targeted deletion of endothelial lipase increases HDL particles with anti-inflammatory properties both in vitro and in vivo.

Authors:  Tetsuya Hara; Tatsuro Ishida; Yoko Kojima; Hanayo Tanaka; Tomoyuki Yasuda; Masakazu Shinohara; Ryuji Toh; Ken-ichi Hirata
Journal:  J Lipid Res       Date:  2010-10-06       Impact factor: 5.922

Review 2.  Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.

Authors:  Hiroshi Fukui
Journal:  World J Hepatol       Date:  2015-03-27

3.  LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria.

Authors:  N Lamping; R Dettmer; N W Schröder; D Pfeil; W Hallatschek; R Burger; R R Schumann
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

4.  Serum amyloid P component prevents high-density lipoprotein-mediated neutralization of lipopolysaccharide.

Authors:  C J de Haas; M J Poppelier; K P van Kessel; J A van Strijp
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

5.  Endotoxin contamination of apolipoprotein A-I: effect on macrophage proliferation--a cautionary tale.

Authors:  Xueting Jin; Qing Xu; Keith Champion; Howard S Kruth
Journal:  Atherosclerosis       Date:  2015-03-09       Impact factor: 5.162

6.  Apolipoprotein A-I binding to anionic vesicles and lipopolysaccharides: role for lysine residues in antimicrobial properties.

Authors:  Wendy H J Beck; Christopher P Adams; Ivan M Biglang-Awa; Arti B Patel; Heather Vincent; Eric J Haas-Stapleton; Paul M M Weers
Journal:  Biochim Biophys Acta       Date:  2013-02-26

7.  Serum lipoproteins attenuate macrophage activation and Toll-Like Receptor stimulation by bacterial lipoproteins.

Authors:  Sylvette Bas; Richard W James; Cem Gabay
Journal:  BMC Immunol       Date:  2010-09-16       Impact factor: 3.615

8.  LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction.

Authors:  A C Vreugdenhil; A M Snoek; C van 't Veer; J W Greve; W A Buurman
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

9.  Apolipoprotein A-II augments monocyte responses to LPS by suppressing the inhibitory activity of LPS-binding protein.

Authors:  Patricia A Thompson; Jimmy F P Berbée; Patrick C N Rensen; Richard L Kitchens
Journal:  Innate Immun       Date:  2008-12       Impact factor: 2.680

10.  Apolipoprotein A-I inhibits LPS-induced atherosclerosis in ApoE(-/-) mice possibly via activated STAT3-mediated upregulation of tristetraprolin.

Authors:  Kai Yin; Shi-lin Tang; Xiao-hua Yu; Guang-hui Tu; Rong-fang He; Jin-feng Li; Di Xie; Qing-jun Gui; Yu-chang Fu; Zhi-sheng Jiang; Jian Tu; Chao-ke Tang
Journal:  Acta Pharmacol Sin       Date:  2013-04-08       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.